IRS1 and 2 Signaling in Mammary Development and Cancer
IRS1 和 2 信号在乳房发育和癌症中的作用
基本信息
- 批准号:6620551
- 负责人:
- 金额:$ 26.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-01-15 至 2006-12-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (provided by applicant) The long-term goal of these studies is to
understand the function and importance of insulin receptor substrates (IRSs) in
mammary development and tumorigenesis. IRSs, a family of proteins that
integrate and co-ordinate signals from growth factors, cytokines, and
integrins, are hormonally regulated in breast cancer cell lines, and have
prognostic significance in breast cancer. But almost nothing is known about the
roles of IRSs in the stages of normal breast development and involution, which
could help us interpret their role in the onset of cancer. We have therefore
chosen to study IRSs during mammary development in the mouse, as this system
has been well characterized and can be genetically manipulated.
We find that there are dramatic changes in IRS localization, levels, and
activation during pregnancy, lactation, and involution. We propose that these
changes reflect a critical role for IRSs in mammary development. Specifically,
we hypothesize that IRSs are hormone-regulated during virgin development,
providing both proliferative and survival signals. Increased expression of IRSs
during pregnancy supplies further proliferative and survival signals that
promote lobuloalveolar development. However, following lactation, IRS-generated
survival signals must be turned off, to allow the mammary gland to undergo
apoptosis-mediated involution. We will test these hypotheses in three Specific
Aims. 1) How do steroid hormones regulate the distinct localization patterns of
IRS-1 and -2 in ductal mammary epithelium, and are the levels or patterns of
IRS-1 or -2 critical for ductal and lobuloalveolar development? 2) Do IRSs
provide survival signals during lactation that are turned off by rapid
ubiquitin-mediated degradation of IRSs at the onset of involution? 3) Will
forced overexpression of IRS-1 or -2 result in aberrant IRS signaling and cause
mammary hyperplasia or overt tumorigenesis, or promote carcinogen-induced
tumorigenesis? The role of IRSs in integrating growth factor and steroid
hormone signals in both normal and malignant breast cells makes it essential to
understand how they work in both settings. Knowing their function in normal
development may make it possible to understand the dysfunction in abnormal
development, and perhaps even to devise interventions to block or reverse the
onset of full malignancy.
描述:(由申请人提供)这些研究的长期目标是
了解胰岛素受体底物(IRSs)的功能和重要性,
乳腺发育和肿瘤发生。IRSs是一个蛋白质家族,
整合和协调来自生长因子、细胞因子
整合素,在乳腺癌细胞系中受到神经调节,
乳腺癌的预后意义。但几乎没有人知道
IRS在正常乳房发育和退化阶段的作用,
可以帮助我们解释它们在癌症发病中的作用。我们因此
选择在小鼠乳房发育期间研究IRSs,因为该系统
已经得到了很好的表征,并且可以进行基因操纵。
我们发现,IRS的定位、水平和
在妊娠、哺乳和退化期间激活。我们建议,这些
这些变化反映了IRS在乳腺发育中的关键作用。具体地说,
我们假设IRSs在处女发育期间是受免疫调节的,
提供增殖和存活信号。IRS表达增加
在怀孕期间提供进一步的增殖和存活信号,
促进小叶肺泡发育。然而,哺乳后,IRS产生的
必须关闭生存信号,让乳腺经历
退化介导的退化。我们将在三个具体的测试这些假设
目标。1)类固醇激素是如何调节
IRS-1和IRS-2在乳腺导管上皮中的表达,是IRS-1和IRS-2在乳腺导管上皮中的水平或模式。
IRS-1或-2对导管和小叶肺泡发育至关重要?2)做IRS
在哺乳期间提供生存信号,这些信号被快速的
泛素介导的退化的IRS开始退化?3)将
IRS-1或IRS-2的强制过表达导致异常的IRS信号传导,
乳腺增生或明显的肿瘤发生,或促进致癌物质诱导
肿瘤发生胰岛素抵抗系统在整合生长因子和激素中的作用
正常和恶性乳腺细胞中的激素信号使得
了解它们在这两种环境中的工作原理。了解它们在正常情况下的功能
发展可能使我们有可能了解异常的功能障碍,
发展,甚至可能制定干预措施,以阻止或扭转
完全恶性肿瘤的发病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adrian V Lee其他文献
Adrian V Lee的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adrian V Lee', 18)}}的其他基金
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
用于转化研究的侵袭性小叶乳腺癌模型认证
- 批准号:
10219509 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
用于转化研究的侵袭性小叶乳腺癌模型认证
- 批准号:
10589777 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer
雌激素受体融合基因作为乳腺癌内分泌抵抗的驱动因素
- 批准号:
10219505 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer
雌激素受体融合基因作为乳腺癌内分泌抵抗的驱动因素
- 批准号:
10605355 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Estrogen receptor fusions genes as drivers of endocrine resistance in breast cancer
雌激素受体融合基因作为乳腺癌内分泌抵抗的驱动因素
- 批准号:
10373094 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Developing and credentialing murine models of ILC
ILC 小鼠模型的开发和认证
- 批准号:
10830524 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
High-Throughput Computing for Genomics and Bioinformatics Research
用于基因组学和生物信息学研究的高通量计算
- 批准号:
10176848 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
用于转化研究的侵袭性小叶乳腺癌模型认证
- 批准号:
10378642 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Targeting the IGF Pathway for Treatment of Breast Cancer
靶向 IGF 通路治疗乳腺癌
- 批准号:
7385535 - 财政年份:2007
- 资助金额:
$ 26.62万 - 项目类别:
IGF-1& its Cross-Talk with Estrogen in Breast Tumor Grow
胰岛素样生长因子1
- 批准号:
6989330 - 财政年份:2004
- 资助金额:
$ 26.62万 - 项目类别:
相似海外基金
Developing multitarget enzyme inhibitors as safe and effective anti-migraine treatments
开发多靶点酶抑制剂作为安全有效的抗偏头痛治疗方法
- 批准号:
10714658 - 财政年份:2023
- 资助金额:
$ 26.62万 - 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
- 批准号:
10395608 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
- 批准号:
10576908 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Novel Enzyme Inhibitors in the Innate Immune Evasion Repertoire of Staphylococci
葡萄球菌先天免疫逃避库中的新型酶抑制剂
- 批准号:
10166534 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
The Development and Study of Novel Lipopeptide Antibiotics and Enzyme Inhibitors
新型脂肽抗生素和酶抑制剂的开发与研究
- 批准号:
RGPIN-2017-04233 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Discovery Grants Program - Individual
Novel Enzyme Inhibitors in the Immune Evasion Repertoire of Staphylococcus aureus (Equipment Supplement)
金黄色葡萄球菌免疫逃逸的新型酶抑制剂(设备补充)
- 批准号:
10796329 - 财政年份:2021
- 资助金额:
$ 26.62万 - 项目类别:
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
- 批准号:
10259832 - 财政年份:2020
- 资助金额:
$ 26.62万 - 项目类别:
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
- 批准号:
10642850 - 财政年份:2020
- 资助金额:
$ 26.62万 - 项目类别:
The Development and Study of Novel Lipopeptide Antibiotics and Enzyme Inhibitors
新型脂肽抗生素和酶抑制剂的开发与研究
- 批准号:
RGPIN-2017-04233 - 财政年份:2020
- 资助金额:
$ 26.62万 - 项目类别:
Discovery Grants Program - Individual
Utility of Centrally Acting Angiotensin Converting Enzyme Inhibitors to slow the progression of Dementia
中枢作用血管紧张素转换酶抑制剂减缓痴呆进展的效用
- 批准号:
10408178 - 财政年份:2020
- 资助金额:
$ 26.62万 - 项目类别:














{{item.name}}会员




